Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2003 1
2005 1
2013 1
2014 1
2017 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Pillai M, Jiang Y, Lorigan PC, Thistlethwaite FC, Thomas M, Kirillova N, Bridgeman JS, Kueberuwa G, Biswas S, Velazquez P, Chonzi D, Guest RD, Roberts ZJ, Hawkins RE. Pillai M, et al. Among authors: guest rd. Am J Cancer Res. 2022 Aug 15;12(8):3967-3984. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119832 Free PMC article.
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kühlcke K, Westwood N, Thistlethwaite F, Hawkins RE, Gilham DE. Guest RD, et al. Cancer Immunol Immunother. 2014 Feb;63(2):133-45. doi: 10.1007/s00262-013-1492-9. Epub 2013 Nov 5. Cancer Immunol Immunother. 2014. PMID: 24190544 Clinical Trial.
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE. Thistlethwaite FC, et al. Among authors: guest rd. Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28. Cancer Immunol Immunother. 2017. PMID: 28660319 Free PMC article. Clinical Trial.